publication date: Mar. 22, 2019
To access this members-only content, please log in.Institutional subscribers, please
log in with your IP.
If you're not a subscriber why not
join today? To gain access to the members only content
click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.
The Cancer Prevention and Research Institute of Texas—the second largest publicly-funded granting organization for cancer after NIH—may receive $3 billion more to stay open past its current sunset date in 2023.
Advocates of renewing the Cancer Prevention and Research Institute of Texas argue that the agency is a good investment for the state.
- Françoise Mornex becomes first female recipient of Heine H. Hansen Award
- Gift to UPMC Children’s Hospital of Pittsburgh establishes treatment suite for rare early childhood cancer
The FY19 Defense Appropriation provides $100 million to the Department of Defense Prostate Cancer Research Program to support innovative, high-impact prostate cancer research.
Many have written and spoken about the goal of eliminating the effect of developing and delivering medical care in “silos.”
- Breast ultrasound and cancer detection rates increased under new laws
- Duke study says genomic testing associated with lower health care costs in high-risk breast cancer patients
- Braftovi with Mektovi + Erbitux or panitumumab recommended in advanced BRAF-mutant colorectal
- Data from GARNET study indicates robust activity of dostarlimab in endometrial cancer
- Tecentriq + chemo gets FDA approval in extensive-stage SCLC
- Strata Oncology launches expanded StrataNGS
- Oncoceutics and NCI collaborate to develop ONC206
- FDA issues warning letters to breast implant manufacturers to deliver on post-approval requirements
